Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (337)	11/9/2006 12:47:50 PM
From: Jim Oravetz	Read Replies (1) of 370

Vion Pharm 3Q Loss Widens On 63% Increase In Costs >VION DOW JONES NEWSWIRES November 9, 2006 8:46 a.m. Vion Pharmaceuticals Inc.'s (VION) third-quarter loss widened as total costs rose 63%, partly on larger research and development expenses. The development-stage biopharmaceutical concern said Thursday its quarterly loss widened to $6.3 million, or 10 cents a share, from $3.7 million, or 6 cents a share, a year earlier. Revenue remained flat at $6,000. The New Haven, Conn., company's total operating expenses increased to $6.84 million from $4.2 million on higher preclinical development costs and share-based compensation expenses. Vion ended September with $36.2 million in cash and cash equivalents, down from $52.8 million at the end of 2005.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next